TheraRadar
Data updated: May 26, 2026

TEGSEDI (inotersen sodium)

First-in-Class Orphan Drug Priority Review Fast Track
CNS Approved 2018-10-05
1
Indication
--
Phase 3 Trials
1
Priority Reviews
7
Years on Market

Details

Status
Discontinued
First Approved
2018-10-05
Patent Cliff
2031

Pro Metrics

Patent cliff and revenue data

Unlock with Pro
Routes
SUBCUTANEOUS
Dosage Forms
SOLUTION

Companies

Active Ingredient: INOTERSEN SODIUM

TEGSEDI Approval History

2019
2020
2021
2022
2023
2024
2025
2026
Original
New Indication
New Form
Label Update
9 FDA actions from 2018 to 2024
Nov 2024 SUPPL
Update · REMS
Jan 2024 SUPPL
Label · Labeling
Mar 2023 SUPPL
Update · REMS

What TEGSEDI Treats

1 FDA approvals

Originally approved for its first indication in 2018 .

  • Other (1)
📋

Clinical Trial Registry

1 trials
Trial Sponsor ID Phase Status Title
NCT04306510 results posted TEG4004 Ph 4 terminated A Study to Characterize Adverse Events Occurring Within One Day of TEGSEDI Administration to Adult Participants With hATTR-PN
🔬

Active Pipeline

Pro

Ongoing clinical trials by development phase

Loading...

Key Completed Trials

Pro

Completed studies with published results, ranked by significance

Loading...
📊

Trial Timeline

Full development history with FDA approval milestones

|
Loading...
Understanding FDA Approval Types
Count Type What it means
- ORIG Original approval - drug first enters market
- SUPPL - Efficacy New indication (new disease/condition approved)
- SUPPL - Labeling Label text changes (warnings, dosing updates)
- SUPPL - Manufacturing Production changes (new facility)
- SUPPL - Chemistry Formulation changes (new dosage strength)

Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.

TEGSEDI FDA Label Details

View full patent landscape →
3 OB patents · 1 families · 58 international docs across 26 countries

TEGSEDI Patents & Exclusivity

Latest Patent: Apr 2031

Patents (3 active)

US9399774 Expires Apr 29, 2031
US9061044 Expires Apr 29, 2031
US8697860 Expires Apr 29, 2031
Source: FDA Orange Book

Pro Intelligence Preview

Deep insights for TEGSEDI

Revenue Insights

  • Quarterly revenue tracking
  • Historical trend analysis

Patent Timeline

  • Cliff: 2031
  • 3 active patents

Trial Analysis

  • Clinical trial tracking
  • Development stage analysis

Competitive Landscape

  • Competitor tracking
  • Same target/indication analysis
Unlock Full Intelligence

Full approval history • All patents • Revenue trends • Competitor analysis

Data Sources

Data sourced from official FDA and NIH databases. Click links to verify on original sources.